Cytotoxicity evaluation of curcumin-loaded affibody-decorated liposomes against breast cancerous cell lines

References

• Ahlgren., S., et al., 2009. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. Journal of nuclear medicine: official publication, society of nuclear medicine, 50 (5), 781–789
   PubMed Web of Science ®Google Scholar
• Akhtari., J., et al., 2016. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors. International journal of pharmaceutics, 505 (1–2), 89–95
   PubMed Web of Science ®Google Scholar
• Alam., S., Panda, J.J., and Chauhan, V.S., 2012. Novel dipeptide nanoparticles for effective curcumin delivery. International journal of nanomedicine, 7, 4207–4222
   PubMed Web of Science ®Google Scholar
• Allijn., I.E., Schiffelers, R.M., and Storm, G., 2016. Comparison of pharmaceutical nanoformulations for curcumin: Enhancement of aqueous solubility and carrier retention. International journal of pharmaceutics, 506 (1-2), 407–413
   PubMed Web of Science ®Google Scholar
• Altai., M., et al., 2014. 188Re-ZHER2: V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment. Journal of nuclear medicine: official publication, society of nuclear medicine, 55 (11), 1842–1848
   PubMed Web of Science ®Google Scholar
• Barui., S., et al., 2014. Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature. Biomaterials, 35 (5), 1643–1656
   PubMed Web of Science ®Google Scholar
• Catania., A., et al., 2013. Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. Breast cancer research and treatment, 141 (1), 55–65
   PubMed Web of Science ®Google Scholar
• Chen., Y., et al., 2012. Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics. Molecules, 17 (5), 5972–5987
   PubMed Web of Science ®Google Scholar
• Dhule, S.S., et al., 2012. Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine: nanotechnology, biology, and medicine, 8, 440–451.
   Google Scholar
• Eslaminejad., T., Ansari, M., and Elaminejad, T., 2012a. Evaluation of the Potential of Trichoderma viride in the Control of Fungal Pathogens of Roselle (Hibiscus sabdariffa) in vitro. Microbial pathogenesis, 52 (4), 201–205
   PubMed Web of Science ®Google Scholar
• Eslaminejad., T., Zakaria, M., and Eslaminejad, T., 2012b. Anti-fungal activity of cold and hot water extracts of spices against fungal pathogens of Roselle (Hibiscus sabdariffa) in vitro. Microbial pathogenesis, 52 (2), 125–129
   PubMed Web of Science ®Google Scholar
• Feng., T., et al., 2017. Liposomal curcumin and its application in cancer. International journal of nanomedicine, 12, 6027–6044
   PubMed Web of Science ®Google Scholar
• Filippi., A., et al., 2019. Anticancer effects of curcumin in luminal B and HER2 breast cancer cell line models. Romanian biotechnological letters, 24 (1), 168–175
   Web of Science ®Google Scholar
• Fulda., S., 2010. Modulation of apoptosis by natural products for cancer therapy. Planta medica, 76 (11), 1075–1079
   PubMed Web of Science ®Google Scholar
• Ghanemi., M., et al., 2018. Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate. Current cancer drug targets, 19 (1), 65–73
   Web of Science ®Google Scholar
• Hasan., M., et al., 2014. Liposome encapsulation of curcumin: physico-chemical characterizations and effects on MCF7 cancer cell proliferation. International journal of pharmaceutics, 461 (1-2), 519–528
   PubMed Web of Science ®Google Scholar
• Ibrahim., S., et al., 2018. Curcumin marinosomes as promising nano-drug delivery system for lung cancer. International journal of pharmaceutics, 540 (1–2), 40–49
   PubMed Web of Science ®Google Scholar
• Klibanov., A.L., et al., 1991. Activity of amphipathic poly (ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochimica et biophysica acta (bba) - biomembranes, 1062 (2), 142–148
   PubMedGoogle Scholar
• Lee., S.B., et al., 2008. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clinical cancer research: an official journal of the american association for cancer research, 14 (12), 3840–3849
   PubMed Web of Science ®Google Scholar
• Löfblom., J., et al., 2010. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS letters, 584 (12), 2670–2680
   PubMed Web of Science ®Google Scholar
• Ohadi, M., et al., 2017. Antioxidant potential and wound healing activity of biosurfactant produced by Acinetobacter junii B6. Current pharmaceutical biotechnology, 18, 900–908.
   Google Scholar
• Ranjan., A.P., et al., 2013. Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: inhibition of tumor growth and angiogenesis. Anticancer research, 33, 3603–3609
   PubMed Web of Science ®Google Scholar
• Salehiabar, M., et al., 2018. Production of biological nanoparticles from bovine serum albumin as controlled release carrier for curcumin delivery. International journal of biological macromolecules, 115, 83–89.
   PubMed Web of Science ®Google Scholar
• Santosh., M., et al., 2012. Paleoproterozoic ultrahigh-temperature granulites in the North China Craton: implications for tectonic models on extreme crustal metamorphism. Precambrian research, 222, 77–106
   Web of Science ®Google Scholar
• Serwotka-Suszczak., A.M., et al., 2017. A conjugate based on anti-HER2 diaffibody and auristatin E targets HER2-positive cancer cells. International journal of molecular sciences, 18 (2), 401
   Web of Science ®Google Scholar
• Shanmugam., M.K., et al., 2015. The multifaceted role of curcumin in cancer prevention and treatment. Molecules, 20 (2), 2728–2769
   PubMed Web of Science ®Google Scholar
• Sochaj-Gregorczyk, A.M., et al., 2017. Design and in vitro evaluation of a cytotoxic conjugate based on the anti-HER2 affibody fused to the Fc fragment of IgG1. International journal of molecular sciences, 18 (8), 1688.
   Web of Science ®Google Scholar
• Trousil., S., et al., 2014. Positron emission tomography imaging with 18F-labeled ZHER2: 2891 affibody for detection of HER2 expression and pharmacodynamic response to HER2-modulating therapies. Clinical cancer research, 20 (6), 1632–1643
   PubMed Web of Science ®Google Scholar
• Yan., M., et al., 2015. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer metastasis reviews, 34 (1), 157–164
   PubMed Web of Science ®Google Scholar
• Zahmatkeshan., M., et al., 2016. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model. European journal of pharmaceutical sciences: official journal of the European federation for pharmaceutical sciences, 86, 125–135
   PubMed Web of Science ®Google Scholar
• Zokaei, E., et al., 2019. Therapeutic potential of DNAzyme loaded on chitosan/cyclodextrin nanoparticle to recovery of chemosensitivity in the MCF-7 cell line. Applied biochemistry and biotechnology, 187, 708–723.
   Google Scholar